Well Done LLC Grows Position in Pfizer Inc. (NYSE:PFE)

Well Done LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 13.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,052 shares of the biopharmaceutical company’s stock after purchasing an additional 1,285 shares during the quarter. Well Done LLC’s holdings in Pfizer were worth $318,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. State Street Corp grew its stake in Pfizer by 1.9% in the 2nd quarter. State Street Corp now owns 287,201,692 shares of the biopharmaceutical company’s stock valued at $10,534,558,000 after purchasing an additional 5,374,611 shares during the period. Moneta Group Investment Advisors LLC grew its stake in shares of Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after acquiring an additional 160,963,976 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after acquiring an additional 9,393,992 shares during the period. Morgan Stanley grew its stake in shares of Pfizer by 0.4% during the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after acquiring an additional 348,628 shares during the period. Finally, Norges Bank bought a new position in shares of Pfizer during the 4th quarter worth $3,150,472,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. Truist Financial dropped their price objective on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Friday, March 1st. Finally, UBS Group lowered their price target on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Trading Up 0.5 %

Shares of PFE traded up $0.14 during mid-day trading on Wednesday, hitting $27.73. 20,058,911 shares of the company’s stock traded hands, compared to its average volume of 43,642,293. The firm has a market capitalization of $157.02 billion, a P/E ratio of 77.14, a PEG ratio of 1.23 and a beta of 0.61. The business’s 50-day moving average price is $27.48 and its 200-day moving average price is $29.52. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $42.22. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 earnings per share. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.